KRW 3710.0
(-2.62%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 580.64 Million KRW | -94.25% |
2022 | 10.09 Billion KRW | -34.15% |
2021 | 15.32 Billion KRW | 7329.77% |
2020 | 206.25 Million KRW | 104.99% |
2019 | -4.13 Billion KRW | 0.0% |
2018 | - KRW | 0.0% |
2017 | - KRW | 0.0% |
2016 | - KRW | 0.0% |
2015 | - KRW | 0.0% |
2014 | - KRW | 0.0% |
2013 | - KRW | 0.0% |
2012 | - KRW | 0.0% |
2011 | - KRW | 0.0% |
2010 | - KRW | 0.0% |
2009 | - KRW | 0.0% |
2008 | - KRW | 0.0% |
2007 | - KRW | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | 534.09 Million KRW | 0.0% |
2024 Q3 | 14.66 Billion KRW | 7.05% |
2024 Q2 | 13.7 Billion KRW | 1370000000100.0% |
2023 Q2 | 163.83 Million KRW | -98.39% |
2023 Q1 | 10.2 Billion KRW | 1.09% |
2023 FY | 580.64 Million KRW | -94.25% |
2023 Q4 | 580.64 Million KRW | 0.24% |
2023 Q3 | 579.23 Million KRW | 253.55% |
2022 Q2 | 10.18 Billion KRW | -33.21% |
2022 Q3 | 10.13 Billion KRW | -0.48% |
2022 FY | 10.09 Billion KRW | -34.15% |
2022 Q4 | 10.09 Billion KRW | -0.42% |
2022 Q1 | 15.24 Billion KRW | -0.51% |
2021 Q2 | 12.79 Billion KRW | 8191.23% |
2021 Q3 | 15.29 Billion KRW | 19.51% |
2021 Q4 | 15.32 Billion KRW | 0.2% |
2021 FY | 15.32 Billion KRW | 7329.77% |
2021 Q1 | 154.34 Million KRW | -25.17% |
2020 Q4 | 206.25 Million KRW | 99.89% |
2020 FY | 206.25 Million KRW | 104.99% |
2020 Q3 | 103.18 Million KRW | -8.53% |
2020 Q2 | 112.8 Million KRW | -29.85% |
2020 Q1 | 160.8 Million KRW | 0.0% |
2019 Q3 | - KRW | 0.0% |
2019 Q1 | - KRW | 0.0% |
2019 Q2 | - KRW | 0.0% |
2019 Q4 | - KRW | 0.0% |
2019 FY | -4.13 Billion KRW | 0.0% |
2018 Q1 | - KRW | 0.0% |
2018 FY | - KRW | 0.0% |
2018 Q4 | - KRW | 0.0% |
2018 Q3 | - KRW | 0.0% |
2018 Q2 | - KRW | 0.0% |
2017 Q2 | - KRW | 0.0% |
2017 FY | - KRW | 0.0% |
2017 Q4 | - KRW | 0.0% |
2017 Q3 | - KRW | 0.0% |
2017 Q1 | - KRW | 0.0% |
2016 Q1 | - KRW | 0.0% |
2016 FY | - KRW | 0.0% |
2016 Q3 | - KRW | 0.0% |
2016 Q4 | - KRW | 0.0% |
2016 Q2 | - KRW | 0.0% |
2015 Q3 | - KRW | 0.0% |
2015 Q2 | - KRW | 0.0% |
2015 Q1 | - KRW | 0.0% |
2015 FY | - KRW | 0.0% |
2015 Q4 | - KRW | 0.0% |
2014 FY | - KRW | 0.0% |
2014 Q4 | - KRW | 0.0% |
2014 Q3 | - KRW | 0.0% |
2014 Q1 | - KRW | 0.0% |
2014 Q2 | - KRW | 0.0% |
2013 Q3 | - KRW | 0.0% |
2013 FY | - KRW | 0.0% |
2013 Q4 | - KRW | 0.0% |
2013 Q1 | - KRW | 0.0% |
2013 Q2 | - KRW | 0.0% |
2012 Q4 | - KRW | 0.0% |
2012 Q1 | - KRW | 0.0% |
2012 FY | - KRW | 0.0% |
2011 FY | - KRW | 0.0% |
2011 Q4 | - KRW | 0.0% |
2011 Q3 | - KRW | 0.0% |
2011 Q2 | - KRW | 0.0% |
2011 Q1 | - KRW | 0.0% |
2010 Q4 | - KRW | 0.0% |
2010 Q1 | - KRW | 0.0% |
2010 Q3 | - KRW | 0.0% |
2010 FY | - KRW | 0.0% |
2010 Q2 | - KRW | 0.0% |
2009 Q2 | - KRW | 0.0% |
2009 Q4 | - KRW | 0.0% |
2009 Q3 | - KRW | 0.0% |
2009 Q1 | - KRW | 0.0% |
2009 FY | - KRW | 0.0% |
2008 Q2 | - KRW | 0.0% |
2008 Q3 | - KRW | 0.0% |
2008 Q1 | - KRW | 0.0% |
2008 FY | - KRW | 0.0% |
2008 Q4 | - KRW | 0.0% |
2007 Q2 | - KRW | 0.0% |
2007 Q3 | - KRW | 0.0% |
2007 Q1 | - KRW | 0.0% |
2007 FY | - KRW | 0.0% |
2007 Q4 | - KRW | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Yuyu Pharma, Inc. | 13.64 Billion KRW | 95.743% |
Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 99.713% |
Ildong Holdings Co., Ltd. | 29.87 Billion KRW | 98.057% |
HANDOK Inc. | 123.78 Billion KRW | 99.531% |
Kukje Pharma Co., Ltd. | 475.74 Million KRW | -22.05% |
Yuhan Corporation | 60.23 Billion KRW | 99.036% |
Dong-A ST Co., Ltd. | 161.99 Billion KRW | 99.642% |
SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -470.28% |
Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 99.292% |
Hanall Biopharma Co.,Ltd | 590.3 Million KRW | 1.637% |
Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 90.403% |
Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | 96.865% |
MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | 95.386% |
Hana Pharm Co., Ltd. | 1.59 Billion KRW | 63.683% |
Yuyu Pharma, Inc. | 13.64 Billion KRW | 95.743% |
Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -385.172% |
REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 99.52% |
Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 98.185% |
JW Holdings Corporation | 20.65 Billion KRW | 97.189% |
Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | 96.083% |
Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 98.065% |
JW Pharmaceutical Corporation | 30 Billion KRW | 98.065% |
Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -165.182% |
Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 98.829% |
Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | 86.958% |
Yuyu Pharma, Inc. | 13.64 Billion KRW | 95.743% |
Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | 96.948% |
Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 99.378% |
JW Pharmaceutical Corporation | 30 Billion KRW | 98.065% |
Yuhan Corporation | 60.23 Billion KRW | 99.036% |
Jeil Pharma Holdings Inc | 10.5 Billion KRW | 94.47% |
Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 98.562% |
Suheung Co., Ltd. | 74 Billion KRW | 99.215% |
JW Pharmaceutical Corporation | 30 Billion KRW | 98.065% |
Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | 86.064% |
Korea United Pharm Inc. | 10.96 Billion KRW | 94.703% |
CKD Bio Corp. | 69.43 Billion KRW | 99.164% |
Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 98.321% |
Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | 96.4% |
Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -89.101% |
Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -165.182% |
Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 99.195% |
Boryung Corporation | 151.7 Billion KRW | 99.617% |
Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 99.261% |
Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 90.403% |
JW Lifescience Corporation | 168 Million KRW | -245.623% |